Automate Your Wheel Strategy on ZTS
With Tiblio's Option Bot, you can configure your own wheel strategy including ZTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZTS
- Rev/Share 20.7462
- Book/Share 10.3999
- PB 14.5203
- Debt/Equity 1.4501
- CurrentRatio 1.7362
- ROIC 0.2254
- MktCap 67230860080.0
- FreeCF/Share 5.0961
- PFCF 29.4743
- PE 26.8436
- Debt/Assets 0.4788
- DivYield 0.0128
- ROE 0.5132
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ZTS | Leerink Partners | Outperform | Market Perform | -- | $155 | July 17, 2025 |
| Downgrade | ZTS | Stifel | Buy | Hold | -- | $160 | June 18, 2025 |
News
USNA or ZTS: Which Is the Better Value Stock Right Now?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
Zoetis Inc. is the dominant animal health company, growing market share, revenue, and margins, now trading at a multi-year low valuation. Fundamentals remain strong: rising EPS, aggressive buybacks, and a shareholder yield of 3.2% with robust secular tailwinds supporting long-term growth. Key franchises (Simparica, Apoquel, Librela) are expanding, protected by patents, into the 2030s-2040s, with further growth potential from under-penetrated markets.
Read More
Here's Why Zoetis (ZTS) is a Strong Growth Stock
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Should You Invest in Zoetis (ZTS) Based on Bullish Wall Street Views?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS).
Read More
Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded.
Published: June 18, 2025 by: Barrons
Sentiment: Negative
The Merck rival faces intense competition that could limit multiple expansion, Stifel analysts say.
Read More
Top Stock Movers Now: Jabil, Oracle, Zoetis, and More
Published: June 18, 2025 by: Investopedia
Sentiment: Positive
U.S. equities were higher at midday as President Donald Trump again called on Federal Reserve Chair Jerome Powell to cut interest rates ahead of today's Fed decision. The Dow Jones Industrial Average, S&P 500, and Nasdaq all gained.
Read More
Here's Why Zoetis (ZTS) is a Strong Momentum Stock
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
Read More
Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?
Read More
DSNKY vs. ZTS: Which Stock Is the Better Value Option?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Drugs stocks have likely encountered both Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY) and Zoetis (ZTS).
Read More
The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks
Published: June 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
His concentrated portfolio strategy, focusing on high-quality, long-term holdings, reflects a disciplined, tech-heavy investment approach.
Read More
Zoetis Inc. (ZTS) William Blair 45th Annual Growth Stock Conference (Transcript)
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (NYSE:ZTS ) William Blair 45th Annual Growth Stock Conference June 3, 2025 11:40 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Brandon Vazquez - William Blair Brandon Vazquez Right. Good morning, everyone.
Read More
Top 15 High-Growth Dividend Stocks For June 2025
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, though still short of my 12% annualized target. The June 2025 Top 15 stocks offer a 1.34% average dividend yield with a 22.82% 5-year dividend growth rate and are 25% undervalued.
Read More
Why Zoetis (ZTS) is a Top Momentum Stock for the Long-Term
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Zoetis Inc. (ZTS) Stifel 2025 Jaws & Paws Conference (Transcript)
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (NYSE:ZTS ) Stifel 2025 Jaws & Paws Conference May 29, 2025 9:10 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Jon Block - Stifel Jon Block Great. Thank you.
Read More
Dr. Mark Stetter Elected to Zoetis Board of Directors
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He wil.
Read More
Zoetis (ZTS) Upgraded to Buy: Here's Why
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Wall Street Analysts Think Zoetis (ZTS) Could Surge 26.18%: Read This Before Placing a Bet
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services
Published: May 09, 2025 by: CNBC Television
Sentiment: Neutral
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.
Read More
Zoetis' Q1: Market Overreaction Or Justified Drop?
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
The market did not like Zoetis Inc. earnings despite strong growth and the evidence that Zoetis is becoming a better business. Buybacks continued throughout the quarter and Zoetis is a good example of how consistent buybacks can become significant over long periods. Despite competitive pressures, key franchises like Simparica and Apoquel continue to grow. This portrays one of the attractive characteristics of the animal health industry.
Read More
Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis shares have underperformed, losing 8% over the past year, but recent solid earnings and guidance suggest shares are nearer to fair value, shifting my stance from "sell" to "hold.". The company reported $1.48 EPS, beating estimates, with 9% organic growth despite foreign exchange headwinds; US dollar weakness should boost future results. Zoetis maintains a strong balance sheet, with $1.7 billion cash and $6.6 billion debt, supporting shareholder returns through buybacks and dividends.
Read More
Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (NYSE:ZTS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazquez - William Blair Chris Schott - JPMorgan Navann Ty - BNP Paribas Daniel Clark - Leerink Partners Operator Welcome to the First Quarter 2025 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve …
Read More
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
Read More
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Zoetis (ZTS) Surpasses Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $1.38 per share a year ago.
Read More
Zoetis Announces First Quarter 2025 Results
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company reported revenue of $2.2 billion for the first quarter of 2025, an increase of 1% compared with the first quarter of 2024. On an organic operational1 basis, revenue for the first quarter of 2025 increased 9% compared with the first quarter of 2024. Net income for the first quarter of 2025 was $631 million, or $1.41 per.
Read More
MKKGY vs. ZTS: Which Stock Is the Better Value Option?
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Merck KGaA (MKKGY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
About Zoetis Inc. (ZTS)
- IPO Date 2013-02-01
- Website https://www.zoetis.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Kristin C. Peck
- Employees 13800